Merck’s Enflonsia Approved in EU for RSV Prevention in Infants Without Weight-Based Dosing

Why It Matters

A weight‑free dosing regimen simplifies RSV prophylaxis, potentially expanding coverage to both healthy and high‑risk infants and reducing healthcare‑system complexity across Europe.

Key Takeaways

• Fixed 105 mg dose replaces weight‑based calculations
• CLEVER trial cut RSV hospitalizations by 84%
• SMART interim data matched palivizumab safety profile
• EU approval enables market entry in 30+ countries

Pulse Analysis

Merck’s Enflonsia marks a pivotal shift in RSV prevention strategy for European infants. By securing European Commission endorsement, the drug joins a narrow class of long‑acting monoclonal antibodies that can protect newborns for roughly five months—the typical RSV season. The fixed 105 mg dose eliminates the cumbersome weight‑based calculations that have limited the uptake of existing prophylactics such as palivizumab, making it easier for pediatricians and neonatal units to administer a single injection shortly after birth. This regulatory win also aligns with Merck’s broader global rollout, following approvals in the United States, Canada, and Switzerland, and positions the company to capture a sizable share of a market estimated at several hundred million euros annually.

The clinical foundation for Enflonsia rests on robust data from the CLEVER and SMART trials. In CLEVER, more than 3,600 infants experienced a 60.4% drop in medically attended RSV lower‑respiratory infections and an 84.2% decline in hospitalizations through 150 days, with protection persisting for six months. SMART, focusing on high‑risk children, demonstrated safety and pharmacokinetic profiles comparable to the established palivizumab, reinforcing confidence in the fixed‑dose approach. Across both studies, adverse events were mild, primarily injection‑site reactions, underscoring a favorable risk‑benefit balance for a vulnerable population.

For European healthcare systems, Enflonsia’s simplified dosing could translate into operational efficiencies and broader vaccine‑like coverage, especially in regions where weight‑based dosing has been a barrier. Reimbursement decisions will shape the speed of commercial availability, but the drug’s potential to curb RSV‑related hospital stays may appeal to payers seeking cost‑containment. Competitors may be prompted to explore fixed‑dose formulations, accelerating innovation in the infant prophylaxis space. As RSV continues to impose a heavy seasonal burden, Enflonsia offers a timely, scalable solution that could reshape preventive care for the continent’s youngest patients.